Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6667) 6667
Newsletter (451) 451
Newspaper Article (434) 434
Book Chapter (110) 110
Magazine Article (34) 34
Book / eBook (7) 7
Trade Publication Article (5) 5
Conference Proceeding (3) 3
Publication (2) 2
Transcript (2) 2
Book Review (1) 1
Dissertation (1) 1
Government Document (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5464) 5464
science & technology (4031) 4031
life sciences & biomedicine (3932) 3932
scleroderma (3924) 3924
female (3402) 3402
middle aged (2596) 2596
systemic scleroderma (2512) 2512
male (2509) 2509
adult (2218) 2218
scleroderma, systemic - drug therapy (2196) 2196
rheumatology (2019) 2019
scleroderma, systemic - complications (1720) 1720
systemic sclerosis (1686) 1686
aged (1390) 1390
biological and medical sciences (1264) 1264
medical sciences (1258) 1258
abridged index medicus (890) 890
treatment outcome (865) 865
dermatology (835) 835
sarcoidosis. granulomatous diseases of unproved etiology. connective tissue diseases. elastic tissue diseases. vasculitis (773) 773
scleroderma, systemic - pathology (746) 746
care and treatment (682) 682
research (679) 679
fibrosis (666) 666
scleroderma, systemic - physiopathology (659) 659
scleroderma, systemic - diagnosis (613) 613
animals (566) 566
skin (553) 553
skin - pathology (542) 542
immunosuppressive agents - therapeutic use (514) 514
scleroderma, systemic - immunology (504) 504
patients (499) 499
medical research (488) 488
medicine & public health (487) 487
drug therapy (474) 474
immunology (465) 465
adolescent (463) 463
lung diseases (430) 430
scleroderma, systemic - therapy (421) 421
autoimmune diseases (407) 407
analysis (395) 395
medicine, experimental (378) 378
risk factors (378) 378
clinical trials (375) 375
pulmonary hypertension (374) 374
general & internal medicine (366) 366
health aspects (365) 365
arthritis (360) 360
scleroderma, systemic - metabolism (358) 358
prognosis (340) 340
scleroderma, localized - drug therapy (335) 335
medicine, general & internal (325) 325
severity of illness index (308) 308
child (307) 307
lupus (307) 307
biopsy (301) 301
pharmacology. drug treatments (299) 299
diseases of the osteoarticular system (296) 296
diagnosis (293) 293
collagen (287) 287
mice (286) 286
integumentary system (285) 285
time factors (282) 282
disease (281) 281
systemic lupus erythematosus (280) 280
scleroderma, systemic - blood (274) 274
rheumatoid arthritis (273) 273
research article (270) 270
retrospective studies (260) 260
hypertension (259) 259
development and progression (258) 258
drug therapy, combination (254) 254
fibroblasts (253) 253
autoimmunity (252) 252
inflammation (252) 252
gene expression (248) 248
follow-up studies (246) 246
hypertension, pulmonary - drug therapy (246) 246
raynaud disease - drug therapy (242) 242
mortality (239) 239
internal medicine (238) 238
medicine (234) 234
young adult (231) 231
hypertension, pulmonary - etiology (228) 228
cyclophosphamide - therapeutic use (226) 226
prospective studies (223) 223
diagnosis, differential (221) 221
disease models, animal (215) 215
pathogenesis (212) 212
case-control studies (210) 210
cells, cultured (209) 209
scleroderma, systemic - genetics (207) 207
scleroderma, localized - pathology (205) 205
cyclophosphamide (204) 204
fibroblasts - metabolism (204) 204
skin and connective tissue diseases (204) 204
rheumatoid factor (200) 200
penicillamine - therapeutic use (195) 195
skin - drug effects (195) 195
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7014) 7014
German (225) 225
French (172) 172
Russian (93) 93
Italian (84) 84
Japanese (76) 76
Polish (64) 64
Spanish (42) 42
Portuguese (20) 20
Chinese (17) 17
Czech (13) 13
Danish (6) 6
Croatian (5) 5
Hebrew (5) 5
Hungarian (5) 5
Ukrainian (5) 5
Romanian (4) 4
Swedish (4) 4
Dutch (3) 3
Korean (2) 2
Norwegian (2) 2
Finnish (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
by Distler, Oliver and Highland, Kristin B and Gahlemann, Martina and Azuma, Arata and Fischer, Aryeh and Mayes, Maureen D and Raghu, Ganesh and Sauter, Wiebke and Girard, Mannaig and Alves, Margarida and Clerisme-Beaty, Emmanuelle and Stowasser, Susanne and Tetzlaff, Kay and Kuwana, Masataka and Maher, Toby M and SENSCIS Trial Investigators
The New England journal of medicine, ISSN 0028-4793, 06/2019, Volume 380, Issue 26, pp. 2518 - 2528
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Enzyme Inhibitors - adverse effects | Lung Diseases, Interstitial - etiology | Double-Blind Method | Administration, Oral | Humans | Middle Aged | Male | Diarrhea - chemically induced | Enzyme Inhibitors - therapeutic use | Lung Diseases, Interstitial - drug therapy | Disease Progression | Vital Capacity | Indoles - adverse effects | Scleroderma, Systemic - complications | Adult | Female | Indoles - therapeutic use | Lung Diseases, Interstitial - physiopathology | Scleroderma, Systemic - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Drug therapy | Sclerosis | Tyrosine | Mycophenolic acid | Sensitivity analysis | Lung diseases | Rheumatology | Oral administration | Clinical trials | Diarrhea | Patients | Pulmonary hypertension | Pulmonary fibrosis | Computed tomography | Systemic sclerosis | Technical communication | Fibrosis | Skin | Scleroderma | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
by Kowal-Bielecka, O and Landewé, R and Avouac, J and Chwiesko, S and Miniati, I and Czirjak, L and Clements, P and Denton, C and Farge, D and Fligelstone, K and Földvari, I and Furst, D E and Müller-Ladner, U and Seibold, J and Silver, R M and Takehara, K and Toth, B Garay and Tyndall, A and Valentini, G and van den Hoogen, F and Wigley, F and Zulian, F and Matucci-Cerinic, Marco and EUSTAR and EUSTAR Co-Authors and and the EUSTAR co-authors
Annals of the Rheumatic Diseases, ISSN 0003-4967, 05/2009, Volume 68, Issue 5, pp. 620 - 628
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Biological and medical sciences | Medical sciences | Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis | Diseases of the osteoarticular system | Lung Diseases, Interstitial - etiology | Evidence-Based Medicine - methods | Raynaud Disease - drug therapy | Humans | Gastrointestinal Diseases - etiology | Kidney Diseases - drug therapy | Treatment Outcome | Raynaud Disease - etiology | Lung Diseases, Interstitial - drug therapy | Gastrointestinal Diseases - drug therapy | Scleroderma, Systemic - complications | Hypertension, Pulmonary - drug therapy | Kidney Diseases - etiology | Hypertension, Pulmonary - etiology | Scleroderma, Systemic - drug therapy | Medical research | Care and treatment | Usage | Systemic scleroderma | Scleroderma (Disease) | Medicine, Experimental | Reports | Management | Evidence-based medicine | Disease | Antibiotics | Experts | Mortality | Ulcers | Quality | Committees | Rheumatism | Scleroderma | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Systemic sclerosis: from pathogenesis to targeted therapy
by Denton, Christopher P and Denton, Christopher P
Clinical and experimental rheumatology, ISSN 0392-856X, 2015, Volume 33, Issue 4, pp. S3 - S7
Vasculopathy | Scleroderma | Systemic sclerosis | Cytokine | Fibrosis | Growth factor | Life Sciences & Biomedicine | Rheumatology | Science & Technology | Inflammation Mediators - immunology | Humans | Immunosuppressive Agents - therapeutic use | Scleroderma, Systemic - metabolism | Treatment Outcome | Scleroderma, Systemic - immunology | Molecular Targeted Therapy | Remission Induction | Scleroderma, Systemic - diagnosis | Animals | Signal Transduction - drug effects | Inflammation Mediators - metabolism | Immunosuppressive Agents - adverse effects | Scleroderma, Systemic - drug therapy | Index Medicus
Journal Article
Details down arrow
4. Full Text Systemic sclerosis and localized scleroderma—current concepts and novel targets for therapy
by Distler, Oliver and Distler, Oliver and Cozzio, Antonio and Cozzio, Antonio
Seminars in immunopathology, ISSN 1863-2297, 1/2016, Volume 38, Issue 1, pp. 87 - 95
Localized scleroderma | Biomedicine | Immunology | Serotonin | Systemic sclerosis | Soluble guanylate cyclase | Nintedanib | Internal Medicine | Interleukin-6 | Pathology | Life Sciences & Biomedicine | Science & Technology | Scleroderma, Localized - etiology | Scleroderma, Localized - metabolism | Interleukin-6 - therapeutic use | Scleroderma, Localized - drug therapy | Scleroderma, Systemic - etiology | Protein Kinase Inhibitors - therapeutic use | Humans | Scleroderma, Systemic - metabolism | Serotonin Antagonists - therapeutic use | Guanylate Cyclase - metabolism | Molecular Targeted Therapy | Scleroderma, Systemic - drug therapy | Systemic scleroderma | Mortality | Scleroderma (Disease) | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series
by Ferri, Clodoveo and Giuggioli, Dilia and Raimondo, Vincenzo and L'Andolina, Massimo and Tavoni, Antonio and Cecchetti, Riccardo and Guiducci, Serena and Ursini, Francesco and Caminiti, Maurizio and Varcasia, Giuseppe and Gigliotti, Pietro and Pellegrini, Roberta and Olivo, Domenico and Colaci, Michele and Murdaca, Giuseppe and Brittelli, Raffaele and Mariano, Giuseppa Pagano and Spinella, Amelia and Bellando-Randone, Silvia and Aiello, Vincenzo and Bilia, Silvia and Giannini, Daiana and Ferrari, Tommaso and Caminiti, Rodolfo and Brusi, Veronica and Meliconi, Riccardo and Fallahi, Poupak and Antonelli, Alessandro and COVID-19 & ASD Italian Study Grp and COVID-19 & ASD Italian Study Group and for the COVID-19 & ASD Italian Study Group
Clinical rheumatology, ISSN 0770-3198, 11/2020, Volume 39, Issue 11, pp. 3195 - 3204
Life Sciences & Biomedicine | Rheumatology | Science & Technology | Arthritis, Psoriatic - epidemiology | Autoimmune Diseases - physiopathology | Glucocorticoids - therapeutic use | Undifferentiated Connective Tissue Diseases - epidemiology | Pandemics | Rheumatic Diseases - drug therapy | Arthritis, Psoriatic - physiopathology | Humans | Middle Aged | Coronavirus Infections - physiopathology | Male | Dermatomyositis - physiopathology | COVID-19 | Rheumatic Diseases - epidemiology | SARS-CoV-2 | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Arthritis, Rheumatoid - drug therapy | Dermatomyositis - drug therapy | Arthritis, Psoriatic - drug therapy | Scleroderma, Systemic - physiopathology | Lupus Erythematosus, Systemic - drug therapy | Sjogren's Syndrome - epidemiology | Spondylitis, Ankylosing - epidemiology | Aged, 80 and over | Betacoronavirus | Adult | Female | Arthritis, Rheumatoid - physiopathology | Autoimmune Diseases - drug therapy | Antirheumatic Agents - therapeutic use | Autoimmune Diseases - epidemiology | Lupus Erythematosus, Systemic - epidemiology | Sjogren's Syndrome - drug therapy | Spondylitis, Ankylosing - drug therapy | Arthritis, Rheumatoid - epidemiology | Dermatomyositis - epidemiology | Sjogren's Syndrome - physiopathology | Spondylitis, Ankylosing - physiopathology | Undifferentiated Connective Tissue Diseases - physiopathology | Scleroderma, Systemic - epidemiology | Pneumonia, Viral - physiopathology | Undifferentiated Connective Tissue Diseases - drug therapy | Rheumatic Diseases - physiopathology | Italy - epidemiology | Aged | Lupus Erythematosus, Systemic - physiopathology | Scleroderma, Systemic - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma
by Gerber, Elizabeth E and Gallo, Elena M and Fontana, Stefani C and Davis, Elaine C and Wigley, Fredrick M and Huso, David L and Dietz, Harry C
Nature (London), ISSN 0028-0836, 2013, Volume 503, Issue 7474, pp. 126 - 130
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Fibrosis - drug therapy | Antibodies, Antinuclear - immunology | Scleroderma, Systemic - pathology | Skin Diseases, Genetic - drug therapy | Male | Integrins - metabolism | Mutation, Missense - genetics | Contracture - drug therapy | Plasma Cells - drug effects | T-Lymphocytes, Helper-Inducer - drug effects | Antibodies, Neutralizing - immunology | Autoimmunity - immunology | Antibodies, Neutralizing - therapeutic use | Integrins - drug effects | Transforming Growth Factor beta - antagonists & inhibitors | Dendritic Cells - drug effects | Female | Contracture - prevention & control | Microfilament Proteins - metabolism | Skin Diseases, Genetic - prevention & control | Contracture - immunology | Fibrosis - prevention & control | Microfilament Proteins - genetics | Transforming Growth Factor beta - immunology | Microfilament Proteins - chemistry | Fibrillin-1 | Skin Diseases, Genetic - immunology | Contracture - pathology | Skin Diseases, Genetic - pathology | Antibodies, Neutralizing - pharmacology | Fibrillins | Scleroderma, Systemic - immunology | Animals | Amino Acid Substitution - genetics | Mice | Fibrosis - pathology | Amino Acid Motifs - genetics | Autoimmunity - drug effects | Scleroderma, Systemic - drug therapy | Scleroderma, Systemic - prevention & control | Autoimmunity | Cell interaction | Systemic scleroderma | Scleroderma (Disease) | Research | Prevention | Complications and side effects | Fibrosis | Physiological aspects | Dosage and administration | Drug therapy | Molecular biology | Health aspects | Integrins | Flow cytometry | Cell culture | Cytokines | Rodents | Collagen | Mutation | Scleroderma | Age | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease
by Daoussis, Dimitrios, MD and Melissaropoulos, Konstantinos, MD and Sakellaropoulos, Georgios and Antonopoulos, Ioannis, MD and Markatseli, Theodora E., MD and Simopoulou, Theodora, MD and Georgiou, Panagiotis, MD and Andonopoulos, Andrew P., MD and Drosos, Alexandros A., MD and Sakkas, Lazaros, MD, DM, PhD(UK), FRCP(UK) and Liossis, Stamatis-Nick, MD
Seminars in arthritis and rheumatism, ISSN 0049-0172, 2017, Volume 46, Issue 5, pp. 625 - 631
Rheumatology | Rituximab | B cells | Scleroderma | Interstitial lung disease | Systemic sclerosis | Fibrosis | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Male | Lymphocyte Depletion | Case-Control Studies | Time Factors | Scleroderma, Systemic - complications | Adult | Female | Retrospective Studies | Immunosuppressive Agents - administration & dosage | Skin - pathology | Rituximab - adverse effects | Lung - pathology | Kaplan-Meier Estimate | Lung Diseases, Interstitial - complications | Lung Diseases, Interstitial - drug therapy | Rituximab - administration & dosage | B-Lymphocytes - drug effects | B-Lymphocytes - immunology | Lung - drug effects | Immunosuppressive Agents - adverse effects | Aged | Scleroderma, Systemic - drug therapy | Skin - drug effects | Systemic scleroderma | Comparative analysis | Lung diseases | Scleroderma (Disease) | Medical research | Medicine, Experimental | Mycophenolate mofetil | Methotrexate | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
by Khanna, Dinesh, Prof and Denton, Christopher P, Prof and Jahreis, Angelika, MD and van Laar, Jacob M, Prof and Frech, Tracy M, MD and Anderson, Marina E, FRCP and Baron, Murray, MD and Chung, Lorinda, MD and Fierlbeck, Gerhard, MD and Lakshminarayanan, Santhanam, MD and Allanore, Yannick, Prof and Pope, Janet E, MD and Riemekasten, Gabriela, Prof and Steen, Virginia, Prof and Müller-Ladner, Ulf, Prof and Lafyatis, Robert, MD and Stifano, Giuseppina, MD and Spotswood, Helen, PhD and Chen-Harris, Haiyin, PhD and Dziadek, Sebastian, PhD and Morimoto, Alyssa, PhD and Sornasse, Thierry, PhD and Siegel, Jeffrey, MD and Furst, Daniel E, Prof
The Lancet (British edition), ISSN 0140-6736, 06/2016, Volume 387, Issue 10038, pp. 2630 - 2640
Internal Medicine | Medicine(all) | Multicenter Study | Clinical Trial, Phase II | Randomized Controlled Trial | Research Support, Non-U.S. Gov't | Journal Article | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biomarkers - metabolism | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Europe | Humans | Middle Aged | Scleroderma, Systemic - metabolism | Male | Treatment Outcome | United Kingdom | Canada | Vital Capacity | Antibodies, Monoclonal, Humanized - administration & dosage | Injections, Subcutaneous | Scleroderma, Systemic - complications | Interleukin-6 - physiology | Adult | Female | Aged | Scleroderma, Systemic - drug therapy | Medical colleges | Adults | Systemic scleroderma | Interleukins | Scleroderma (Disease) | Analysis | Cytokines | Ulcers | Biomarkers | Fibroblasts | Clinical trials | Patient safety | Skin diseases | Skin | Health risk assessment | Scleroderma | Drug therapy | Tissues | Pathogenesis | Interleukin | Evidence-based medicine | Itching | Interleukin 6 | Cost-benefit analysis | Safety | Thickening | Effectiveness | Mortality | Lung diseases | Medical treatment | Rheumatology | Patients | Studies | Systemic sclerosis | Least squares | Autoimmune diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights